The severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or specifically address CV events in COVID-19 patients. The identification of molecular partners contributing to CV manifestations in COVID-19 patients is crucial for providing early biomarkers, prognostic predictors, and new therapeutic targets. The current report will focus on the role of microRNAs (miRNAs) in CV complications associated with COVID-19. Indeed, miRNAs have been proposed as valuable biomarkers and predictors of both cardiac and vascular damage occurring in SARS-CoV-2 infection.
Cardiovascular Implications of microRNAs in Coronavirus Disease 2019 / Izzo, C.; Visco, V.; Gambardella, J.; Junior Ferruzzi, G.; Rispoli, A.; Rusciano, M. R.; Toni, A. L.; Virtuoso, N.; Carrizzo, A.; Di Pietro, P.; Iaccarino, G.; Vecchione, C.; Ciccarelli, M.. - In: THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. - ISSN 1521-0103. - 384:1(2023), pp. 102-108. [10.1124/jpet.122.001210]
Cardiovascular Implications of microRNAs in Coronavirus Disease 2019
Gambardella J.;Rusciano M. R.;Virtuoso N.;Iaccarino G.;
2023
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or specifically address CV events in COVID-19 patients. The identification of molecular partners contributing to CV manifestations in COVID-19 patients is crucial for providing early biomarkers, prognostic predictors, and new therapeutic targets. The current report will focus on the role of microRNAs (miRNAs) in CV complications associated with COVID-19. Indeed, miRNAs have been proposed as valuable biomarkers and predictors of both cardiac and vascular damage occurring in SARS-CoV-2 infection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
